In its financial results for the third quarter of 2020 Ionis Pharmaceuticals, Inc. reports the advance in the IONIS-PKK-LRx program:
- Proof-of-concept data from the PKK development program in patients with HAE were reported in the New England Journal of Medicine
- Enrollment completed in the IONIS-PKK-LRx Phase 2 study in patients with HAE
- IONIS-PKK-LRx advanced into an investigator-initiated study in hospitalized COVID-19 patients in Brazil
Among the company’s upcoming catalysts is the IONIS-PKK-LRx Phase 2 study in patients with HAE.
(Source: Ionis)
